{"slideshow_credits": null, "snippet": "Under the deal, Bavarian Nordic could receive as much as $975 million to license its advanced prostate cancer treatment, Prostvac.", "abstract": null, "section_name": "Business Day", "print_page": "", "document_type": "article", "byline": {"person": [{"firstname": "Chad", "role": "reported", "lastname": "BRAY", "rank": 1, "organization": ""}], "original": "By CHAD BRAY"}, "web_url": "http://www.nytimes.com/2015/03/05/business/dealbook/bristol-myers-squibb-enters-drug-licensing-deal-with-danish-biotechnology-firm.html", "lead_paragraph": "Under the deal, Bavarian Nordic could receive as much as $975 million to license its advanced prostate cancer treatment, Prostvac.", "headline": {"main": "Bristol-Myers Squibb Enters Drug Licensing Deal With Danish Biotechnology Firm"}, "_id": "54f7c52638f0d8579fff5f51", "word_count": "138", "multimedia": [], "pub_date": "2015-03-05T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Bristol Myers Squibb Company", "is_major": "N", "rank": "1"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "2"}, {"name": "subject", "value": "Prostate Cancer", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Clinical Trials", "is_major": "N", "rank": "4"}, {"name": "glocations", "value": "Denmark", "is_major": "N", "rank": "5"}, {"name": "organizations", "value": "Bavarian Nordic AS", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}